Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR).

PLoS One · 2019 · PMC6752944 · PMID 31536556

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

showed a trendp = 0.051so close (0.05 < p ≤ 0.1)

As a consequence, the estimated incidence of treatment failure showed a trend to being higher in the everolimus than in the control group (53.2% versus 25.0%, log rank p = 0.051) ( Fig 4 ) ( Table 6 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.